• Users Online: 344
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 41  |  Issue : 1  |  Page : 15-22

Serum thrombopoietin and platelet antibodies in thrombocytopenic patients with chronic hepatitis C virus: clinical application of platelet indices


1 Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt

Correspondence Address:
Tamer A Elbedewy
Department of Internal Medicine, Faculty of Medicine, Tanta University, 51719 Tanta
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-1067.178473

Rights and Permissions

Background Chronic hepatitis C virus (HCV) infection is prevalent in 160 million individuals worldwide. Egypt has the highest prevalence of HCV in the world. HCV is known to cause thrombocytopenia even in the absence of overt hepatic disease. The pathophysiology of thrombocytopenia with chronic HCV is complex. Aims To evaluate serum thrombopoietin (TPO) and platelet antibodies in thrombocytopenic patients with chronic HCV and to assess the diagnostic utility of mean platelet volume (MPV) and platelet distribution width (PDW). Patients and methods The present study included 70 patients with chronic HCV with thrombocytopenia divided into two groups; 20 age-matched and sex-matched HCV patients without thrombocytopenia were also included as controls. Serum TPO, platelet autoantibodies, MPV, and PDW were measured in all participants. Results A significantly lower serum TPO level and platelet count were found with advancing degree of liver fibrosis and activity. Significantly higher MPV and PDW were found in patients with antiplatelet autoantibodies formation. The platelet count showed significant positive correlations with TPO level, MPV, and PDW, and inverse correlations with aspartate aminotransferase, alanine aminotransferase, and viral load. Conclusion The dominant mechanism in mild thrombocytopenic HCV patients was the formation of antiplatelet autoantibodies, whereas in moderate to severe thrombocytopenic patients, the dominant mechanism was combined bone marrow affection and formation of antiplatelet autoantibodies. Serum TPO level was decreased in patients with HCV-induced thrombocytopenia. MPV and PDW may be used as indicators for the dominant mechanism. Egyptian J Haematol 41:-0 ͹ 2016 The Egyptian Society of Haematology.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1205    
    Printed32    
    Emailed0    
    PDF Downloaded182    
    Comments [Add]    

Recommend this journal